Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Codexis, Inc.NASDAQ: CDXS

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables dips below year-ago levels

Q1 FY2026 accounts receivables of $2.48M fell 66.6% year over year, behind the +14.6% change in trailing-twelve-month accounts receivables.

Context

  • Accounts receivables amounted to 12.1% of revenue in FY2025, up 10.0 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -66.6% toward the trailing-twelve-month pace of +14.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.48M+395.5% QoQ
Last fiscal yearDec 2025
$8.51M+579.5% YoY
LTMMar 2026
$3.56M+14.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-66.6%——
1 year+579.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
8.51M USD
Year-over-year change
+579.5%

Accounts Receivables vs competitors

How CDXS compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.6% is the 5th highest of 7, against a peer median of +43.5%.
  • Accounts receivables amounts to 4.6% of revenue for CDXS, versus a peer median of 13.2%.
CDXS Competitors
Accounts Receivables for CDXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CCCCC4 Therapeutics, Inc.LTM Mar 2026$5.15M USD-7.6%-45.1%14.8%
OABIOmniAb, Inc.LTM Mar 2026$4.26M USD+247.4%—14.7%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$4.02M USD+18.0%-59.5%11.6%
CDXSCodexis, Inc.LTM Mar 2026$3.56M USD+14.6%—4.6%
IVVDInvivyd, Inc.LTM Mar 2026$3.46M USD-39.0%—6.2%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$3.38M USD+200.1%—173.6%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$1.01M USD+69.0%—32.0%
TARAProtara Therapeutics, Inc.LTM Mar 2026$0 USD———
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CDXS) —+43.5%-52.3%13.2%

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.28M)(33.59M)(76.24M)(65.28M)(43.97M)
Depreciation & Amortization5.95M10.25M9.92M4.95M5.25M
Deferred Income Tax(2.89M)0000
Stock-Based Compensation11.59M14.53M9.97M13.09M9.62M
Change in Working Capital(7.62M)21.57M(18.22M)(12.02M)6.42M
Accounts Receivables(15.57M)(3.23M)20.25M1.25M8.51M
Inventory(196K)(869K)(656K)886K(19K)
Accounts Payables268K207K2.29M(2.57M)(1.29M)
Other Working Capital7.88M25.46M(40.1M)(11.59M)(784K)
Other Non-Cash Items(19K)(1.48M)21.93M9.85M3.31M
Operating Cash Flow(14.27M)11.28M(52.64M)(49.41M)(19.38M)
Capital Expenditures(13.83M)(8.31M)(4.42M)(4.31M)(4.47M)
Acquisitions (Net)36K29K751K87K5K
Purchases of Investments(7.63M)(5.3M)(1.19M)(90.24M)(57.16M)
Sales of Investments(36K)(29K)440K37.47M85.13M
Other Investing Activities36K29K(440K)00
Investing Cash Flow(21.42M)(13.58M)(4.86M)(56.98M)23.5M
Debt Repayment00029.52M9.89M
Common Stock Issued4.97M913K8.65M31.32M18.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.21M)(1.49M)(485K)(318K)0
Financing Cash Flow3.77M(575K)8.17M60.52M27.93M
Effect of Forex Changes00000
Net Change in Cash(31.92M)(2.87M)(49.33M)(45.87M)32.05M
Free Cash Flow(28.1M)2.98M(57.06M)(53.72M)(23.85M)

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.